Recently, many studies have focused on immune checkpoint molecules, such as CTLA-4 and PD-1/PD-L1, as components of new strategies for cancer therapy, and found that these molecules can significantly regulate the immune function of TICs [41, 42]. The gene discussed is PDCD1; the disease is cancer.